Key clinical point: Adding veliparib to frontline chemotherapy and maintenance for high-grade serous epithelial ovarian cancer significantly extended progression-free survival.
Major finding: Median progression-free survival was 23.5 in the veliparib group versus 17.3 months in the control group.
Study details: The randomized, phase 3 VELIA/GOG-3005 trial of 1,140 patients.
Disclosures: The study was sponsored by AbbVie. Dr. Coleman and Dr. Oaknin reported relationships with numerous pharmaceutical companies.
Coleman RL et al. ESMO 2019, Abstract LBA3-PR.